- Current report filing (8-K)
May 22 2012 - 3:33PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event)
May 22, 2012; (May 9, 2012)
GUIDED THERAPEUTICS, INC.
(Exact Name of Registrant as Specified
in Its Charter)
|
|
|
Delaware
|
0-22179
|
58-2029543
|
(
State or Other Jurisdiction of
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
Incorporation)
|
|
|
|
|
5835 Peachtree Corners East, Suite D
Norcross, Georgia
(Address of Principal Executive Offices)
|
30092
(Zip Code)
|
Registrant's Telephone Number, Including Area
Code:
(770) 242-8723
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
|
|
Section 2.02 Results of Operations and Financial
Condition
On
May 14, 2012, the registrant publicly released its financial results for the first quarter ended March 31, 2012, as more fully
described in the press release, a copy of which is furnished as Exhibit 99.1 hereto and which information is incorporated
herein by reference.
Section 7.01 (Regulation
FD Disclosure)
On
May 15, 2012, the registrant conducted a conference call discussing its financial results for the first quarter ended March 31,
2012 and other matters concerning the operation of the company, as more fully described in the prepared transcript of the call,
a copy of which is furnished as Exhibit 99.2 hereto and which information is incorporated herein by reference.
On May 9, 2012, the registrant
publicly issued a press release announcing that the company had submitted a response to the U.S. Food and Drug Administration
regarding the LuViva® Advanced Cervical Scan premarket approval application and provided additional safety testing information
in support of the CE mark application of the product, as more fully described in the press release, a copy of which is furnished
as Exhibit 99.3 hereto and which information is incorporated herein by reference.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
|
|
Number
|
E
xhibit
|
99.1
|
Press Release dated May 14, 2012
|
99.2
|
Transcript of conference call May 15, 2012
|
99.3
|
Press Release dated May 9, 2012
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
GUIDED THERAPEUTICS, INC
.
|
|
|
|
|
|
|
By:
|
/s/ Mark L. Faupel, Ph.D.
|
|
|
|
Mark L. Faupel, Ph.D.
|
|
|
|
CEO & President
|
|
Date: May 22, 2012
|
|
|
|
Guided Therapeutics (QB) (USOTC:GTHP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Guided Therapeutics (QB) (USOTC:GTHP)
Historical Stock Chart
From Jul 2023 to Jul 2024